Table 4 Drug candidates for SARS-CoV-2 prevention and treatment
Categories | Class | Drug name | Associated glycans or targets | Description | Refs. |
|---|---|---|---|---|---|
Prevention | Natural antibody | GalNAcalpha1-Ser | GalNAc-Ser/Thr (Tn antigen) | Preclinical stage | |
| Â | Â | (Gal)1 (GalNAc)1 | Gal-GalNAc-Ser/Thr (T antigen) | Preclinical stage | |
| Â | Â | FDG-reactive antibodies | Man9-GlcNAc2-Asn | Preclinical stage | |
| Â | Vaccine | (GlcNAc)4 (Man)3 | GlcNAc(2-4)-Man3-GlcNAc2-Asn | PubChem CID: 10148744 | |
| Â | Â | Man5(GlcNAc)2Asn | Man5-GlcNAc2-Asn | PubChem CID: 25229604 | |
Treatment | Neutralizing antibody | VIR-7831 | Glycans at N343 | Phase II & NCT04779879 | |
| Â | Â | VIR-7832 | Glycans at N343 | Phase I/II & NCT04746183 | |
| Â | Â | S309 | Glycans at N343 | Preclinical stage | |
| Â | Lectin | FRIL | Complex-type N-glycans | Preclinical stage | |
| Â | Â | Griffithsin | Oligosaccharides | Phase I & NCT02875119 | |
| Â | Â | Clec4g | Complex-type N-glycans | Preclinical stage | |
| Â | Â | CD209c | Complex-type N-glycans | Preclinical stage | |
| Â | Â | Lentil lectin | oligomannose-type glycans and GlcNAc | Preclinical stage | |
| Â | Galectin-3 inhibitor | TD139 | N-acetyllactosamine moieties | Phase II/III & NCT04473053 | |
| Â | Â | GB1107 | N-acetyllactosamine moieties | Preclinical stage | |
| Â | Â | Belapectin | N-acetyllactosamine moieties | Phase II & NCT04365868 | |
|  | Iminosugars | Castanospermine | α-Glucosidase enzymes | Preclinical stage | |
|  |  | UV-4 | α-Glucosidase enzymes | Preclinical stage | |
|  |  | Celgosivir | α-Glucosidase enzymes | Phase II & NCT00157534 | |
|  |  | Miglustat | α-Glucosidase enzymes | Preclinical stage | |
|  |  | Kifunensine | α-Mannosidase enzymes | Preclinical stage | |
| Â | Sialidase | DAS181 | The sialic acid glycans of virus receptor | Phase 3 & NCT03808922 |
